Processa Pharmaceuticals Inc. (PCSA)
NASDAQ (CM) NASDAQ (CM) Primary Summary
PCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study
Processa Pharmaceuticals stock jumps 122% after a phase II update shows NGC-Cap delivers higher active metabolite exposure with comparable safety in breast cancer.
Why Is Processa Pharmaceuticals (PCSA) Stock Up 29% Today?
Processa Pharmaceuticals (NASDAQ: PCSA ) stock is rising higher on Tuesday after the company posted an update from the Food and Drug Administration (FDA). The FDA has cleared Processa Pharmaceuticals for its Phase 2 clinical trial Next Generation Capecitabine (NGC-Cap).
Processa Pharmaceuticals Inc. (PCSA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Processa Pharmaceuticals Inc. ever had a stock split?
Processa Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | George K. Ng CEO | NASDAQ (CM) Exchange | 74275C403 CUSIP |
| US Country | 10 Employees | - Last Dividend | 17 Dec 2025 Last Split | 10 Oct 2017 IPO Date |
Overview
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, specialized in advancing the development of drug therapies aimed at improving the treatment outcomes of cancer patients. The company primarily focuses on modifying existing FDA-approved oncology drugs to enhance their safety and efficacy. By altering the metabolism and/or distribution of these drugs, Processa Pharmaceuticals aims to maintain their cancer cell-killing mechanisms while potentially reducing side effects and improving patient quality of life. Founded in 2011, Processa Pharmaceuticals is headquartered in Hanover, Maryland, positioning itself as a pioneer in the field of oncological drug development with an emphasis on the reformation of chemotherapy treatments.
Products and Services
Processa Pharmaceuticals' product pipeline consists of advanced chemotherapy drugs, each targeted at a range of cancers. The company leverages modifications of well-known oncology drugs, seeking to optimize their performance and safety profile.
- Capecitabine (PCS6422)
This is a modification of the existing FDA-approved drug capecitabine, aimed at treating metastatic colorectal, gastrointestinal, breast, pancreatic, and other types of cancer. By altering its metabolic pathway, PCS6422 is designed to enhance efficacy while potentially mitigating the side effects commonly associated with traditional chemotherapy treatments.
- Gemcitabine (PCS3117)
PCS3117 is a redesigned form of gemcitabine, focusing on improving the treatment of pancreatic, lung, ovarian, and breast cancers, among others. The modification seeks to offer better distribution within the body, aiming for a more targeted attack on cancer cells with reduced impact on healthy cells, thus aiming to minimize the adverse reactions associated with gemcitabine.
- Irinotecan (PCS11T)
PCS11T represents a novel version of irinotecan for the treatment of lung, colorectal, gastrointestinal, pancreatic, and other cancers. Processa Pharmaceuticals is working to modify this drug to alter its toxicity profile, hoping to lessen the severe gastrointestinal side effects often experienced by patients, making cancer treatment more tolerable.
